How big is your bubble? Characteristics of self-isolating household units ('bubbles') during the COVID-19 Alert Level 4 period in New Zealand: a cross-sectional survey.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
28 01 2021
Historique:
entrez: 29 1 2021
pubmed: 30 1 2021
medline: 9 2 2021
Statut: epublish

Résumé

To characterise the self-isolating household units (bubbles) during the COVID-19 Alert Level 4 lockdown in New Zealand. In this cross-sectional study, an online survey was distributed to a convenience sample via Facebook advertising and the Medical Research Institute of New Zealand's social media platforms and mailing list. Respondents were able to share a link to the survey via their own social media platforms and by email. Results were collected over 6 days during Alert Level 4 from respondents living in New Zealand, aged 16 years and over. The primary outcome was the mean size of a self-isolating household unit or bubble. Secondary outcomes included the mean number of households in each bubble, the proportion of bubbles containing essential workers and/or vulnerable people, and the mean number of times the home was left each week. 14 876 surveys were included in the analysis. The mean (SD) bubble size was 3.58 (4.63) people, with mean (SD) number of households 1.26 (0.77). The proportion of bubbles containing one or more essential workers, or one or more vulnerable persons was 45.3% and 42.1%, respectively. The mean number of times individual bubble members left their home in the previous week was 12.9 (12.4). Bubbles that contained at least one vulnerable individual had fewer outings over the previous week compared with bubbles that did not contain a vulnerable person. The bubble sizes were similar by respondent ethnicity. In this New Zealand convenience sample, bubble sizes were small, mostly limited to one household, and a high proportion contained essential workers and/or vulnerable people. Understanding these characteristics from a country which achieved a low COVID-19 infection rate may help inform public health interventions during this and future pandemics.

Identifiants

pubmed: 33509849
pii: bmjopen-2020-042464
doi: 10.1136/bmjopen-2020-042464
pmc: PMC7844934
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e042464

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Yale J Biol Med. 2005 Oct;78(5):329-34
pubmed: 17132339
J Prev Med Hyg. 2019 Mar 29;60(1):E64-E67
pubmed: 31041413
Health Promot Int. 2020 Dec 10;:
pubmed: 33305323
Emerg Infect Dis. 2010 Jan;16(1):100-2
pubmed: 20031050
Internet Interv. 2016 Apr 27;4:72-81
pubmed: 30135792
Lancet. 2020 May 16;395(10236):1521
pubmed: 32416772
Lancet. 2020 May 9;395(10235):1474
pubmed: 32386582
Emerg Infect Dis. 2012 Jan;18(1):71-7
pubmed: 22257434
JAMA. 2020 May 19;323(19):1915-1923
pubmed: 32275295
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lung India. 2017 Jul-Aug;34(4):349-354
pubmed: 28671166
J Med Internet Res. 2017 Aug 28;19(8):e290
pubmed: 28851679

Auteurs

Nethmi Kearns (N)

Medical Research Institute of New Zealand, Wellington, New Zealand nethmi.kearns@mrinz.ac.nz.

Nick Shortt (N)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Ciléin Kearns (C)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Allie Eathorne (A)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Mark Holliday (M)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Diane Mackle (D)

Medical Research Institute of New Zealand, Wellington, New Zealand.

John Martindale (J)

Medical Research Institute of New Zealand, Wellington, New Zealand.

Alex Semprini (A)

Medical Research Institute of New Zealand, Wellington, New Zealand.
School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.

Mark Weatherall (M)

Medical Research Institute of New Zealand, Wellington, New Zealand.
Department of Medicine, University of Otago Wellington, Wellington, New Zealand.

Richard Beasley (R)

Medical Research Institute of New Zealand, Wellington, New Zealand.
School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
Department of Respiratory Medicine, Capital and Coast Distirct Health Board, Wellington, New Zealand.

Irene Braithwaite (I)

Medical Research Institute of New Zealand, Wellington, New Zealand.
School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH